A white paper by the Tufts Center for the Study of Drug Development, commissioned by Thermo Fisher Scientific, shows that their integrated Accelerator platform combining contract development and manufacturing organizations (CDMOs) with contract research organizations (CROs) can reduce oncology drug development timelines by up to 34 months. The consolidation minimizes delays between clinical trial phases by streamlining decision-making and execution. These results, presented at BIO International, suggest broader applicability to other modalities and indications beyond cancer.